Standard BioTools saw the highest growth of 1.49% in patent filings and 1.49% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.49% and grants by 1.49%. GlobalData’s DataBook provides a comprehensive analysis of Standard BioTools‘s patent filings and grants. Buy the databook here.
Standard BioTools has been focused on protecting inventions in United States(US) with seven publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 17% filings and 62% grants. The World Intellectual Property Organization(WIPO), European Patent Office(EPO), United States(US), and Israel(IL) patent Office are among the top ten patent offices where Standard BioTools is filings its patents. Among the top granted patent authorities, Standard BioTools has 62% of its grants in United States(US), 25% in Japan(JP) and 12% in Israel(IL).
Standard BioTools stands in second position with respect to its patent publications among its competitors.
Patents related to healthtech and machine learning lead Standard BioTools's portfolio
Standard BioTools has the highest number of patents in healthtech followed by, machine learning and electronic medical record (emr) systems. For healthtech, nearly 33% of patents were filed and no patents were granted in Q2 2024.
Autonomous driving related patents lead Standard BioTools portfolio followed by healthcare it, and medical imaging information systems
Standard BioTools has highest number of patents in autonomous driving followed by healthcare it, medical imaging information systems, femtosecond laser, and machine learning.
For comprehensive analysis of Standard BioTools's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.